Quote Tweet
Finally, @Merck publishes its rationale for pursuing certain solid tumors besides #melanoma & #lungcancer with earlier Keytruda monotherapy trials. It was based on molecular profiling of ~16000 primary/met cancers looking at PD-L1, immune signatures.
clincancerres.aacrjournals.org/content/early/
Show this thread
